CPRX - NASDAQ

Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to the Chief Financial Officer, Mike Kalb. Please go ahead, sir.

Thank you. Good morning, everyone, and thank you for joining our conference call to discuss Catalyst's Second Quarter 2025 Financial Results and Business Highlights. Richard Daly, President and CEO, will lead the call today; and Jeffrey Del Carmen, our Chief Commercial Officer, and I will also present. Additionally, Dr. Steven Miller, our Chief Operating Officer and Chief Scientific Officer; and Dr. Will Andrews, our Chief Medical Officer, will be available for the Q&A. Before we begin, I would like to remind you that in our remarks this morning and in the Q&A session, we will make statements about expected future results, which may be forward-looking statements for purposes of federal securities laws. These statements reflect our current expectations, estimates and projections and do not guarantee future performance. They involve risks, uncertainties and assumptions that are difficult to predict and may not prove to be accurate. Actual results may vary from the expectations contained in our forward-looking statements. These forward-looking statements should be considered only in conjunction with our detailed information contained in our SEC filings, including the risk factors described in our 2024 annual report on Form 10-K filed with the SEC on February 26, 2025, and in our second quarter 2025 quarterly report on Form 10-Q, which was filed yesterday, August 6, 2025, with the SEC. At this time, I'll turn the call over to Rich. Rich?

Thanks, Mike. Good morning, everyone, and thank you for joining us. Catalyst delivered another record-setting quarter in Q2 2025 with total revenue reaching $146.6 million, an increase of 19.4% year-over-year. For the first half of 2025, total revenue grew 30.2% to $288 million, reflecting strong execution and sustained demand for our differentiated portfolio. We ended the second quarter of 2025 with a cash position of $652.8 million, reinforcing our ability to invest strategically for long-term growth. Based on strong leading indicators, we remain confident in our trajectory and believe that we are on track to achieve our full year 2025 revenue guidance of $545 million to $565 million. Our outstanding progress is underpinned by the balanced performance of our commercial portfolio, which continues to deliver consistent growth and a positive impact on patients. Let's dive deeper and start with FIRDAPSE. FIRDAPSE generated net product revenue of $84.8 million in Q2 2025, a growth of $7.5 million versus Q2 2024. As we discussed in our Q1 2025 earnings call, last year's second quarter results reflect the timing impact of the February 2024 Change Healthcare cybersecurity breach on our year-over-year growth rate. The temporary impact of the Change Healthcare security breach, which shifted volume from Q1 2024 to Q2 2024 was fully resolved by the end of June 2024. As a result, we believe that comparing FIRDAPSE first half 2025 performance to the same period in 2024 provides the most accurate view of the franchise's continued strength. Importantly, the underlying demand remains strong, consistent and durable. Year-to-date, FIRDAPSE has delivered $168.6 million in net product revenue, representing a 16.9% increase over the first half of 2024. In 2025, our sales of FIRDAPSE have returned to their expected cadence, and we reaffirm our full year 2025 product -- net product revenue guidance of $355 million to $360 million. We are confident that FIRDAPSE remains well positioned for sustained organic growth, supported by consistently high prescription approval rates and a robust pool of patients progressing through their diagnostic journey. This strong and visible demand underscores the durability of our franchise and reinforces our leadership in addressing the needs of the LEMS patient community. To unlock the next phase of growth for FIRDAPSE, we are actively advancing a focused expansion strategy centered on education of HCPs supported by the recent updated NCCN guidelines. Since we believe that potentially 90% of cancer-associated LEMS patients remain undiagnosed, we see a meaningful opportunity to expand our reach in this high potential, underserved population. We expect momentum to build in the months ahead, setting the stage for a sustained growth in 2026 and beyond. Jeff will cover the specifics in his section of the call. While FIRDAPSE continues to perform well, we are equally encouraged by the accelerating adoption and performance of AGAMREE. AGAMREE continues to outperform expectations, generating $27.4 million in net product revenue in Q2 2025, a new post-launch high and a 213% increase year-over-year from Q2 2024. First half net revenues reached $49.4 million, up 398% from the prior year, driven by steady conversion from both Prednisone and EMFLA

Thanks, Rich. Q2 marked another record-setting quarter for our commercial organization, underscoring continued strong execution across the portfolio and sustained demand for our differentiated therapies. As Rich noted, Catalyst delivered sustained organic growth from FIRDAPSE, strong revenues from FYCOMPA and accelerating adoption of AGAMREE. Q2 net product revenue of $146.5 million puts us firmly on track to meet our 2025 guidance, reflecting the strength of our neuroscience business. FIRDAPSE remains the only evidence-based FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome. The brand continues to perform well across both neurology and our emerging oncology segments. FIRDAPSE continues its strong multi-quarter growth trajectory, driven by durable demand and consistent execution. Prescription approval rates remained above 90% across both government and commercial payers and discontinuation rates were in line with expectations, tracking below an annualized rate of 20%. These indicators reflect strong patient adherence and reinforce the foundation for sustained performance. Leading indicators, including steady growth in new patient starts and refill volumes through July continue to trend positively, reinforcing our confidence in achieving full year 2025 FIRDAPSE revenue guidance. We continue to advance our patient identification efforts and continue to have a pool of over 500 LEMS patients in active diagnostic stages. These patients consistently account for approximately half of new starts each quarter, giving us confidence in driving sustained organic growth. To further unlock the next phase of growth for FIRDAPSE, we are actively advancing a focused expansion strategy centered on HCP education, which is supported by the recently updated NCCN guidelines for small cell lung cancer, broadening access to VGCC antibody testing, streamlining the diagnostic journey and accelerating adoption across oncology and neurology settings. By improving diagnosis, particularly in small cell lung cancer patients and increasing recognition of patients often misdiagnosed with myasthenia gravis, we hope to meaningfully expand the addressable population and drive sustained growth within what we believe is a more than $1 billion addressable market opportunity. As we advance these priorities, we are implementing a 3-step program of targeted initiatives designed to enhance diagnostic access and clinical recognition across key market segments. First, we are deploying a frictionless testing model that makes it easier for physicians and particularly oncologists to order BGCC antibody screening directly within their practices, eliminating referral delays and helping to significantly reduce time to diagnosis. These efforts represent progress in advancing important diagnostic initiatives to help improve LEMS patient outcomes and accelerate the adoption of FIRDAPSE. Second, we are pleased to share that ahead of schedule, the NCCN published updated guidelines for small cell lung cancer on July 25, which now include BGCC antibody testing and recommend that amifampridine should be considered as a treatment for cancer patients with LEMS. This milestone strengthens our ability to expand access, accelerate diagnosis and help drive FIRDAPSE adoption in oncology. Most importantly, it represents meaningful progress in improving care for cancer patients living with LEMS. Our third step involves forging strategic partnerships with leading oncology practices to update care pathways, which are generally structured plans that outline the steps and interventions required for patient care, ensuring standardized and efficient treatment for specific conditions. We plan to execute comprehensive education and promotion programs to ensure broad understanding and integration of the care pathways. Due to the early updating of the NCCN guidelines, we are accelerating our investment in educating HCPs on the new guidelines and working to incorporate diagnostic and treatment recommendations into the care pathways in targeted large group oncology practices. Since we believe that potentially 90% of cancer-associated LEMS patients remain undiagnosed, we see a meaningful opportunity to expand our reach in this high potential underserved population. We expect momentum to build in the months ahead, setting the stage for sustained growth in 2026 and beyond. Turning to AGAMREE. AGAMREE continues to demonstrate strong early market momentum as a differentiated treatment for Duchenne Muscular Dystrophy. Q2 2025 net product revenue was $27.4 million. Adoption continues to expand across key centers. To-date, 93% of the top 45 DMD centers of excellence and 231 unique health care providers have submitted enrollment forms. In Q2, approximately 43% of patients transitioned from prednisone and 42% from EMFLA

Thank you, Jeff. Our performance during the second quarter of 2025 has kept us on pace for another strong year, driven by our solid financial performance, financial discipline and strong execution. With the continued success of our flagship product, FIRDAPSE as well as the strong growth of AGAMREE, which we launched in mid-March of 2024 and the solid performance of FYCOMPA, which currently has only one generic competitor for the tablets following the patent expiry in May of 2025, we have set the groundwork for what promises to be yet another unparalleled year in 2025. We are reaffirming our 2025 full year total revenue guidance as initially provided in February and reaffirmed in May. We remain steadfast in our commitment to driving growth and expanding our portfolio to capitalize on emerging opportunities throughout the year. Our total revenues for the second quarter of 2025 were $146.6 million, an approximate 19.4% increase when compared to total revenues of $122.7 million for the second quarter of 2024. Product revenue net for our lead product FIRDAPSE was $84.8 million, a 9.7% increase year-over-year compared to $77.4 million. As a reminder, the second quarter of 2024 benefited from the Change Healthcare cybersecurity incident that occurred in the first quarter of 2024, which is evidenced by the fact that our growth in net product revenue for FIRDAPSE for the first half of 2025 compared to the first half of 2024 was 16.9%. Product revenue net for the second quarter of 2025 for FYCOMPA was $34.3 million compared to $36.5 million in the second quarter of 2024. Product revenue net in the second quarter of 2025 for AGAMREE was $27.4 million as compared to $8.7 million in the second quarter of 2024, representing a year-over-year increase of approximately 213%. Net income before income taxes for the second quarter of 2025 was $69.3 million, a 24.2% increase year-over-year compared to $55.8 million for the second quarter of 2024. We reported GAAP net income for the second quarter of 2025 of $52.1 million or $0.41 per diluted share. GAAP net income increased by 27.7% year-over-year compared to GAAP net income for the second quarter of 2024 of $40.8 million or $0.33 per diluted share. Non-GAAP net income for the second quarter of 2025 was $86.4 million or $0.68 per diluted share, which excludes from GAAP net income; amortization of intangible assets related to our acquisitions of FYCOMPA, AGAMREE and Ruzurgi of $9.3 million; stock- based compensation expense of $7.6 million; income tax provision of $17.2 million and depreciation of $100,000. This compares to non-GAAP net income for the second quarter of 2024 of $69.6 million or $0.56 per diluted share, which excludes from GAAP net income; amortization of intangible assets related to our acquisitions of FYCOMPA, AGAMREE and Ruzurgi of $9.3 million; stock-based compensation expense of $4.4 million; the income tax provision of $15.0 million; and depreciation of $100,000. Our year-to-date effective income tax rate through the first half of 2025 was 22.6% compared to 24.5% through the first half of 2024. The effective tax rate is affected by many factors, including the number of stock options exercised in any given period and is likely to fluctuate in future periods. Cost of sales expense was approximately $20.6 million in the second quarter of 2025 compared to $15.4 million in the second quarter of 2024 and consisted principally of royalties. As a reminder, AGAMREE royalties paid to the product licensor equal 5% of net sales up to $100 million, 7% of net sales in excess of $100 million and up to $200 million with additional increases as net sales increase beyond $200 million. The company is also required to make a $12.5 million sales-based milestone payment once AGAMREE's net product revenue reaches $100 million, [ that ] this milestone payment when earned, will be capitalized and amortized over the estimated remaining useful life of the asset. Further details on our royalty obligations for AGAMREE are disclosed in our Q2 2025 Form 10-Q. Research and development expenses were $4.4 million in the second quarter of 2025, up 46% from $3.0 million in the second quarter of 2024. Our R&D spending in the second quarter of 2025 was comprised mainly of costs to support our ongoing AGAMREE studies. Selling, general and administrative or SG&A expenses for the second quarter of 2025 totaled $45.9 million compared to $40.7 million in the second quarter of 2024. The increase in SG&A expenses for the second quarter of 2025 was primarily driven by increased personnel costs, including the implementation of 2 dedicated sales forces for FIRDAPSE and AGAMREE, which became effective on April 1, 2025. As reported, at June 30, 2025, we had cash and cash equivalents of $652.8 million compared to $517.6 million at December 31, 2024. The increase in cash of $135.2 million was primarily driven by $131.3 million in cash generated from operations of the business, underscoring our continued focus on profit optimization and strong cash flow generation. We believe our current funds, along with our anticipated continued generation of cash from operations, continue to provide us with the financial flexibility to fund our existing R&D programs, meet our potential contractual obligations and support our strategic initiatives, business development and portfolio expansion efforts, leading to long-term growth and value creation. More detailed information and analysis of our second quarter 2025 financial performance may be found in our quarterly report on Form 10-Q, which was filed with the Securities and Exchange Commission yesterday, August 6, 2025, and can be found on the Investor Relations page on our website. At this time, I will turn the call back over to Rich.

Thanks, Mike. As we look ahead, Catalyst remains focused on and confident in our ability to drive sustained growth and long-term value. We are executing a clear strategy rooted in a strong commercial foundation. Our focus and execution will continue to drive our performance and enable us to deliver on our commitments while making a meaningful difference for patients. Our teams are energized by the opportunities ahead, and we remain committed to delivering differentiated therapies with operational excellence and responsible growth. Thank you to our Catalyst teams for their unwavering dedication to patients and to all of you for your continued support. We look forward to continuing to execute our growth initiatives as we advance into the second half of 2025. I'll now turn the call back over to the operator. Thank you.

[Operator Instructions] First question that we have comes from Samantha Semenkow of Citibank.

A couple first on FIRDAPSE. Can you speak more about your strategy for educating oncologists on the LEMS opportunity? And I'm curious what metrics are you using to track the success of the campaign? And then as you continue to focus on the oncology opportunity, when do you expect that segment of the business to begin representing a greater proportion of revenues versus historical experience? I believe in the past, you said it's about 20% to 25% of revenues come from oncology patients.

Thanks, Samantha. I appreciate the question. I'm going to turn that to Jeff. Jeff, do you want to take that one?

Sure. Sam, good to hear from you. As we noted in the script, I think the -- our approach to oncology and the addressable market there for cancer-associated LEMS, the first thing we really wanted to do was increase the -- provide frictionless testing for these patients. And we were able to make that happen where oncologists and all HCPs could order our no-cost VGCC antibody test within their office. So that shortened the time to the diagnostic. Secondly, the NCCN guideline changes. So you heard that in July 25, that -- those changes happen. So those were the first 2 steps. And now we're working on working with the group practices and trying to put together some arrangements with them for screening. So that's the third step. How are we going to educate these physicians? We're focused on digital marketing and media. We're also doing congresses and conferences and publication plan, working with our medical team on that to do abstracts as well. So those are the things that we're doing to help educate physicians about this important opportunity to diagnose LEMS patients. How we're going to track it? Is through increased VGCC antibody testing from oncologists. We're also tracking it, like you said, we anticipate an increase over time of our mix of patients that are cancer-associated LEMS patients. This year, our primary goal is to increase screening for cancer-associated LEMS patients. 90% of these patients are undiagnosed. So if we can help these patients get diagnosed, then we anticipate a larger addressable market that we should start seeing an increase in that percentage in 2026 and beyond. So that's how we're looking at this, Sam.

That's super helpful. Just one follow-up for me. You mentioned on the prepared remarks that there's a Phase I DMD switching study from prednisone or from EMFLA

Thanks, Sam. I'm going to turn that over to Bill Andrews, our Chief Medical Officer. Obviously, we're looking at -- we'll be looking for the data, and I think a lot of that will determine how we leverage it. So obviously, the study is ongoing. So I think it becomes a little challenging to answer your question directly. But Will, do you want to take that?

Yes. Thank you, Rich, and hello, Sam. The study is an exploratory trial, and we are looking forward to seeing data later this year and then early into 2026. And that data will describe -- be descriptive and will help indicate whether we need to do future studies to further delineate potential switching, et cetera.

The next question we have comes from Joon Lee of Truist Securities.

Congrats on the quarter. This is Asim on for Joon. Just a couple from us. So what impact are you seeing on FIRDAPSE and AGAMREE uptake following the increase in sales force size that became effective on April 1? And then as a follow-up on FIRDAPSE, just help us think about this growth over the next few quarters. Should we still be expecting a mid-teens growth rate on a year-over-year basis?

Thanks, Asim. I think, again, it's -- Jeff is going to answer that question. So thanks for the question. Jeff?

Thanks for the question. Like you said, we deployed dedicated sales forces for both AGAMREE and FIRDAPSE in April, so beginning in the second quarter. What we've seen, it's still too early to tell. But based on performance, you can see that there are increased engagements that have taken place. We are -- also deeper relationships now within these accounts and also more frequent interactions with many of the health care providers and our targeted physicians. We're also seeing it from our leading indicators. As I mentioned on the call, with FIRDAPSE, we're exceeding -- or meeting and exceeding the enrollments thus far in July. So very strong, and we also have a strong pipeline there. With AGAMREE too, we've seen the 231 unique physicians that have enrolled since launch. So that also increased from the second quarter. So very, very satisfied with the results thus far, and we'll continue to track that moving forward. As far as performance for FIRDAPSE and what you should expect. We reiterated guidance for the balance of this year. And also, like I just mentioned, the strong leading indicators. So we do believe in our business and the foundation of our business for FIRDAPSE, so we expect continued growth.

The next question we have comes from Jason Gerberry of Bank of America.

A couple for me. Just given all that's going on with ELEVIDYS in the, I guess, nonambulatory group of patients and some of the commentary earlier in the year around queuing, I'm just kind of wondering how that impacts the quarterly kinetics of AGAMREE uptake, if at all? And then with FIRDAPSE, I'm wondering if you could just maybe comment on sort of the time lag for the NCCN recommendation to have more of an impactful commercial impact.

Jason, thanks so much. So from a commercial perspective, we'll take the ELEVIDYS question. We'll turn it over to Jeff. And if they're more of a clinical, we'll have Will jump in on that. But Jeff, do you want to take that one first?

Thanks for the question, Jason. And with AGAMREE and steroids specifically, they are the foundation of treatment for these boys living with DMD. So the impact of the unfortunate news about ELEVIDYS really hasn't impacted much the use of steroids. And we do strongly believe that AGAMREE is the steroid of choice.

Will, do you want to jump in there on the clinical?

Happy to, Rich. Thank you. We see the new additions to the NCCN guidelines as critical to help [ users. ]

[ Is this ] for ELEVIDYS? For DMD.

Yes, I'm sorry.

And the second question was on NCCN. Yes.

On ELEVIDYS, I would add medically that I agree with Jeff from the perspective of that being an entirely different modality of treatment. And as Jeff said, it's unfortunate as to what's happened, but we still see, of course, corticosteroids and vamorolone as foundational treatment for these kids that is unaffected, we believe, by what's happened with ELEVIDYS. To answer your second question on the NCCN guidelines, we see that as critical to helping educate oncologists, clinical oncologists on the disease and very importantly, on how to better diagnose the disease and that amifampridine is a critical option for them in the treatment.

And I'll just add, the way we see the cadence working out, Jeff and the team have done a really good job of getting this frictionless testing in there, which we believe is the first step. So that the physician can order the test and the report will come to their office. Prior to this patient had to actually go to a remote site, get a test and then get the test results themselves. So that's the first step. The NCCN guideline really is the bridge to care pathways within the practice. So as we get this out there, and it was just released, obviously, last week, we get this out there, the opportunity then is to work through those oncology practices get these NCCN guidelines embedded as the standard and NCCN is the true standard within oncology, get that embedded and then begin talking to the group practices about how they want to use it and how we can be supportive. And then as Jeff mentioned earlier on an earlier question, those educational efforts working hand-in-hand with the GPOs and then beyond the GPOs as well become important. Jeff?

Thanks, Rich. And Jason, to your question, when do we expect this to hit commercial and increase some of the net revenue. The way we look at this, again, is increased screening this year and then next year with more patients thankfully being diagnosed, the addressable market increases. And then that can help with the treatment with FIRDAPSE. So we expect that to take place probably in the second half of next year and beyond is when we start seeing converting some of these diagnosed patients onto FIRDAPSE therapy. Hopefully that helps.

The next question we have comes from Leland Gershell of Oppenheimer & Co.

Just one from us, just on OpEx, maybe for Michael. Just wondering, given the realignment in the sales for FIRDAPSE and AGAMREE affected a few months ago. Just wondering how you see SG&A expense rolling forward? It looks like it was pretty flattish from Q1 to Q2. Just wondering if we should see a bit of a bump and the increase into the second half.

Thanks, Leland, and I hope all is well. So as you know, we did not quantify SG&A guidance. We did talk qualitatively at the beginning of the year. Some of the folks that we had hired were in, obviously, a little before April 1. So I think the flat is a little bit to what we'd expect. But to your point, with the acceleration of the NCCN guidelines, I do think that we will see a little bit of an uptick in the second half.

The next question we have comes from Luke Herrmann of Baird.

Two from me. First, on the Change Health disruption. I was wondering if you could share your thoughts on whether all the loose ends have been closed here or if there's potential for any future anomalies. And then second, recent language from the administration on pharma tariffs, which has obviously been sort of constantly evolving. I see that FIRDAPSE is manufactured in the U.S. and Canada. And I think you've had a process underway to consider addition of third- party manufacturers for AGAMREE. I guess, has there been any recent evolution in thinking around the manufacturing strategy?

Thanks, Luke. Thanks for the questions. So the Change Healthcare issue, the disruption we saw there really was -- as we mentioned in the script, really was a pull sort of a push into the second quarter of 2024. We believe and we see the natural cadence of FIRDAPSE returning post June of 2024. And now we believe that effect is washed through the system. So we're very confident about that because we can see -- because of our specialty pharmacy relationship, we can see what's happening there at a very granular level. And you may remember, in our second -- first quarter call in May last year, we mentioned that we saw it the day it began to happen. So we were able to take rapid action. So having that specialty pharmacy is a real benefit for us. On the tariff side, you are correct. When you think about the volume of sales based on our guidance, about 66% of sales come from FIRDAPSE as it relates to our guidance for the year. And we feel really well protected there. And you are also correct on working with third-party manufacturers for AGAMREE, and transitioning that to the U.S. And we were working on that well before this current administration came into play. So we're confident we'll be able to do that in the near term, but it's still going to take a while to actually validate the [ plant. ] But we feel really good about the opportunity to shield that from tariffs as well in the mid- to long term because of the ability to move it to the U.S.

The next question we have comes from Jennifer Kim of Cantor.

Maybe to start with FIRDAPSE. Are there any -- is there any color you can give around the average dose you've reached for the quarter and maybe expectations on that growth for the rest of the year? And then anything you can say about discontinuation rates for the quarter?

Jeff, do you want to take that?

Sure. Thanks, Rich. And yes, the -- first, I'll answer the discontinuation rates. Discontinuation rates were below 20%, the annual discontinuation rate of 20% for FIRDAPSE. So hopefully, were you asking about -- Jennifer, were you asking about FIRDAPSE specifically on discontinuation?

Yes.

Okay. So less than 20% annual discontinuation. And what was your first question again?

Dose.

The dose. So since the label expansion in June of last year, we have seen significant increase to the average daily dose, approximately about 4 milligrams, which is what we had expected. So we -- the dose is performing according to what we had expected.

Okay. That's helpful. And maybe a question on FYCOMPA. I think right now, Teva is the only generic for the oral tablet that's launched. I just want to clarify, do they have a 100-day exclusivity? And I asked because I wonder whether guidance could prove to be on the conservative side for that product.

So Teva is the only player in the space right now for a generic. They have 180-day exclusivity. As to whether or not the guidance is too conservative. So far, as we mentioned in the call, we've booked $70 million in sales. Our guidance is $90 million to $95 million. However, we think that there's an opportunity to be cautious here because this is a significant risk. If there is another generic player that could come into the market, and they have -- we have not seen them yet. And so we're taking what we believe is a prudent position for the balance of the year. And we will expect generic -- additional generic competitors by mid-December. And as you know, Jennifer, sometimes they can load the channel into November. And so that could affect our ex-factory sales. So we believe this is a prudent approach to the forecast.

The next question we have comes from Sudan Loganathan of Stephens Inc.

Catalyst Pharma team, congrats on another strong quarter. First one, I want to ask how you view the potential for PTCT's Translarna FDA approval for DMD treatment to affect how AGAMREE will continue to fit in, retain market share and continue to grow in this space? And then secondly, what is your current stance on near-term strategic initiatives to offset FYCOMPA's LOE? Are there any ongoing discussions with potential partners regarding a commercial stage asset or a late-stage pipeline asset?

I think, it's appropriate to turn that to Jeff for the first part.

Yes, Sudan. Just like -- similar to ELEVIDYS, the way we look at this, is AGAMREE and steroids are [ finest of ] the treatment. Translarna does not impact that at all. So we just continue to feel strongly about AGAMREE's potential moving forward because we do believe it is the best and differentiated steroid out there for boys living with DMD. And as far as...

Well, sorry, Sudan, could you just repeat your question? I lost you for a second. Repeat the second question.

Yes. The second one was just on your current stance on the near-term strategic initiatives to offset the FYCOMPA LOE, if there's any ongoing discussions with either commercial stage asset or late-stage pipeline asset that you're kind of leaning towards in this market environment? Or how you're viewing that going forward?

Thanks for clarifying. So on our business development front as we look to offset -- we think of our business into 2 elements, right? The business development front, bringing in new assets. We are incredibly busy. We believe this is probably one of the best buying environments we've seen in the last 15 or 20 years. And our team is assessing multiple opportunities at any point in time. And as mentioned on previous calls, we continue to see 80% of the opportunities coming to us inbound. So other companies will approach us or other parties will approach us about opportunities. So we're really excited about building -- continuing to build the portfolio. In addition to that, a second pillar of our business is life cycle management. And when we talk about the opportunity around AGAMREE, looking for opportunities to better understand the molecule and how it might play in the orphan and rare space, we continue to do that work. And on the commercial front in diversifying our opportunities with FIRDAPSE, we believe the oncology play and the dedicated sales force can continue to work to offset the loss of FYCOMPA.